间充质干细胞
生物
纤维化
脂肪组织
肾干细胞
干细胞
诱导多能干细胞
肾
肾脏疾病
再生(生物学)
癌症研究
再生医学
免疫学
病理
细胞生物学
医学
内分泌学
祖细胞
胚胎干细胞
生物化学
基因
出处
期刊:Stem Cells and Development
[Mary Ann Liebert]
日期:2018-10-15
卷期号:27 (20): 1406-1411
被引量:15
标识
DOI:10.1089/scd.2017.0304
摘要
As chronic kidney disease progresses, kidney tissue inevitably undergoes cell loss, accumulation of extracellular matrix, and kidney tissue fibrosis, eventually leading to end-stage renal disease. With the continuous innovation of cell therapy technology, mesenchymal stem cells are used in numerous fields, including cardiovascular diseases, diabetes, and kidney tissue injury repair. Adipose-derived mesenchymal stem cells (AMSCs), a type of pluripotent stem cells, have the potential for self-renewal and proliferation with low immunogenicity and significant anti-inflammatory properties. AMSCs can promote impaired cell regeneration and remodeling in renal lesions, thus avoiding further worsening of renal disease and even blocking or reversing the process of renal fibrosis. In this review, we discuss the mechanisms involved in the treatment of renal fibrosis with AMSCs and summarize the potential hazards that may exist in cell therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI